Phase 2
Intervention Type
Subcutaneous (SC) Injection
Funder Type

Drug Details

Leronlimab (PRO 140) inhibits the migration of Tregs into areas of inflammation, which can inhibit the innate immune response against pathogens and, most importantly, the migration of macrophages and release of pro-inflammatory cytokines in lungs. Leronlimab can potentially mitigate the cytokine storm.

Study Purpose

This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection.

Find a Clinical Trial


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >